NGEN — NERVGEN PHARMA CORP.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1751912 ·
Last close
$1.62
Market Cap
$172.39M
52W High
$4.00
52W Low
$1.58
ADV30
756,103
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -7,531,578 | -1,675,549 | — | — | — |
| Dec 2025 | 0 | — | -6,404,283 | -26,908,856 | 23,209,641 | 22,069,635 | 19,732,715 |
| Sep 2025 | 0 | — | -6,170,687 | -4,156,070 | 13,077,452 | 11,364,055 | 16,019,155 |
| Jun 2025 | 0 | — | -6,469,000 | -9,104,187 | 16,923,635 | 15,674,623 | 17,842,056 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,499,211
Investing CF
$100,926
Financing CF
$23,763,937
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-146,763,518
Inventory
—
Receivables
$80,825
ST Investments
$8,369
EBIT TTM
$-25,079,252
Pretax Income TTM
$-44,117,305
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -25,079,252 | -44,117,305 | 23,209,641 | 19,732,715 | — | -19,499,211 |
| Dec 2024 | 0 | -25,176,149 | -24,250,049 | 19,486,223 | 16,909,616 | — | -16,841,034 |
| Dec 2023 | 0 | -17,776,710 | -22,382,120 | 13,236,021 | 15,245,126 | — | -11,295,594 |
| Dec 2022 | 0 | -23,025,033 | -20,722,283 | 23,875,217 | 10,414,137 | — | -17,784,163 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.32
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $1.62 · call oi: 1,996 · put oi: 152
Expected Move to 2026-11-20:
±$2.88
(177.47%) —
implied range
$-1.25 –
$4.50
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | $171.88M | $1.29 | — |
| PYXS | Pyxis Oncology, Inc. | $167.89M | $2.65 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $166.57M | $4.07 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $166.19M | $8.97 | — |
| CAMP | Camp4 Therapeutics Corp | $179.14M | $3.45 | — |
News headlines (Yahoo Finance, 1h cache)
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
2026-05-26 11:15 · Yahoo
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
2026-05-22 03:27 · Yahoo
NervGen Announces Proposed Public Offering of Securities
2026-05-21 20:01 · Yahoo
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-18 11:15 · Yahoo
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
2026-04-27 11:30 · Yahoo
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-13 11:45 · Yahoo
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
2026-04-07 11:30 · Yahoo
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
2026-03-31 11:45 · Yahoo
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
2026-03-12 20:15 · Yahoo
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
2026-03-04 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.